CoChat

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Raltegravir (MK-0518) belongs to the new class of HIV integrase inhibitors. To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs. METHODS: Patients in this phase II study (P004) were antiretroviral treatment naive. Part 1 of this study compared monotherapy with raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily) with placebo over 10 days. In part 2, patients were enrolled for 48 weeks of combination therapy, with randomization to one of the four dosages of raltegravir or to efavirenz, in addition to tenofovir and lamivudine. Mathematical models were used to investigate processes underlying viral dynamics. RESULTS: From day 15 through to day 57, individuals in the raltegravir arm were significantly more likely to have HIV RNA < 50 copies/ml (P < or = 0.047). Plasma viral loads were 70% lower at initiation of second-phase decay for individuals taking raltegravir than for those taking efavirenz (P < 0.0001). This challenges the current hypothesis that second-phase virus originates from infected long-lived cells, as an integrase inhibitor should not impact on viral production from this cell population. Mathematical modeling supported two hypotheses as consistent with these observations: (i) that second-phase virus arises from cells newly infected by long-lived infected cells and (2) that it arises from activation of latently infected cells with full-length unintegrated HIV DNA. CONCLUSIONS: These observations challenge the current understanding of HIV-1 turnover and compartmentalization. They also indicate the promise of this new integrase inhibitor raltegravir.

Overview

Integrity signals

Registry

Crossref · 10.1097/qad.0b013e3282f12377

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 187

Metadata

Authors
Murray, J. M., Emery, S., Kelleher, A. D., Law, M., Chen, J., Hazuda, D. J., Nguyen, B.-Y. T., Teppler, H., & Cooper, D. A.
Affiliations
  • UNSW Sydney (AU)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Murray, John M
Venue
AIDS
Published
2007-11
Volume
21
Issue
17
Pages
2315-2321
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2028179886
Cited by
187
References
22
Citations by year
2024: 1 · 2023: 2 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 14 · 2013: 17 · 2012: 19
FWCI
7.71
Type
journal article
Language
en
Open access
closed
Locations
  • AIDS (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
raltegravir, HIV integrase inhibitors, viral load dynamics, HIV latency, viral compartmentalization, efavirenz, tenofovir, lamivudine, antiretroviral-naive patients, mathematical modeling of viral dynamics
MeSH terms
Tenofovir, Raltegravir Potassium, Adenine, Alkynes, Cyclopropanes, Drug Administration Schedule, Drug Therapy, Combination, HIV, Humans, Organic Chemicals, Pyrrolidinones, RNA, Viral, Time Factors, Virus Replication, HIV Infections, Linear Models, Virus Integration, Virus Latency, Statistics, Nonparametric, Lamivudine, Anti-HIV Agents, HIV Integrase Inhibitors, Viral Load, Benzoxazines, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. https://app.cochat.ai/papers/10.1097/qad.0b013e3282f12377
The paper
Murray, J. M., Emery, S., Kelleher, A. D., Law, M., Chen, J., Hazuda, D. J., Nguyen, B.-Y. T., Teppler, H., & Cooper, D. A. (2007). Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. https://doi.org/10.1097/qad.0b013e3282f12377

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.